Venture Capital Firms in Wyoming

111° West Capital is a multi-stage investment firm that partners with commercial-stage enterprise software companies focused on transforming healthcare delivery and operations.The firm combines a dedicated investment team with an Operator network to provide a hands-on, growth-oriented approach intended to accelerate revenue, scale operations and drive successful exits for portfolio companies.111° West Capital’s public materials and industry profiles indicate a primary focus on digital health and enterprise healthcare software investments, and that the firm was founded in 2021 and is active across stages from commercial growth rounds through Series A/B in its areas of expertise.

Alta Partners is a leading healthcare-focused venture capital firm dedicated to empowering the next generation of healthcare. The firm invests in early-stage biotechnology, life sciences, and technology-enabled healthcare services companies. They aim to partner with entrepreneurs who are building high-impact companies that challenge the status quo and provide better outcomes for patients by integrating physicians, payers, and patients through technology and innovation.Founded in 1996, Alta Partners was established by four senior partners from Burr, Egan, Deleage & Co.: Jean Deleage, Guy Nohra, Garrett Gruener, and Marino Polestra. Burr, Egan, Deleage & Co. was a pioneering venture capital firm with a focus on early-stage investments in life sciences, information technology, and communications. Over its first decade, Alta Partners successfully raised eight venture funds, accumulating over $2 billion in assets under management. In 2017, Pete Hudson and Bob More joined the firm, leading to the launch of the Alta Partners NextGen Funds, which now total over $800 million across four tailored portfolios.Alta Partners boasts a robust portfolio with a strong track record, having contributed to over 75 FDA-approved products and 119 mergers, acquisitions, and IPOs. Notable investments include companies like Kelonia Therapeutics, eGenesis, Tyra Biosciences, Variant Bio, Be Biopharma, Vir Biotechnology, Allakos, and DispatchHealth. These companies span various areas within healthcare, from developing novel therapeutics and gene therapies to pioneering home-based care delivery platforms and solutions for infectious diseases.The investment team at Alta Partners brings decades of collective experience in venture capital, investment banking, operations, and healthcare delivery. They are described as dedicated entrepreneurs, seasoned investors, and trusted partners who take active roles in building companies. Key team members include Managing Directors Dan Janney, Pete Hudson, M.D., and Bob More, along with Chief Financial Officer Larry Randall. The firm emphasizes a long investment horizon and a hands-on approach, working closely with their portfolio companies on the frontlines.

General Catalyst is a prominent global investment and transformation company that partners with entrepreneurs across various stages, from company creation to growth. The firm is dedicated to backing founders who aim to build enduring businesses that contribute to global resiliency and leverage applied artificial intelligence. Beyond traditional venture capital, General Catalyst actively engages in company building, offering strategic guidance and operational support to its portfolio.Founded in 2000 by Joel Cutler and David Fialkow in Cambridge, Massachusetts, General Catalyst has grown significantly over two decades. The firm has expanded its global footprint with offices in major innovation hubs across the United States, Europe, and India. Under the leadership of CEO Hemant Taneja, General Catalyst has pioneered initiatives such as the Health Assurance Transformation Company (HATCo), which focuses on revolutionizing healthcare delivery, and the General Catalyst Institute, a think tank dedicated to shaping global tech policy.With over $43 billion in assets under management, General Catalyst boasts a diverse portfolio of more than 800 companies. Notable investments include industry leaders such as Airbnb, Stripe, Snap, Canva, Anthropic, Anduril, and HubSpot. The firm's investment focus spans critical sectors including Artificial Intelligence, Healthcare, Fintech, Defense & Government, Industrials & Manufacturing, Energy & Infrastructure, Enterprise, and Consumer, demonstrating a commitment to driving transformative change across a broad economic spectrum.

Perceptive Advisors is an investment firm established in 1999, dedicated to advancing the life sciences industry by identifying and funding promising innovations in healthcare. The firm employs a multi-strategy approach, investing across the capital structure in both private and public companies. Their core focus lies in supporting breakthroughs in biotechnology, pharmaceuticals, medical devices, diagnostics, and broader healthcare technologies.Founded in July 1999 by Joseph Edelman, Perceptive Advisors was established with a clear vision to direct financial resources towards the most impactful technologies in modern healthcare. Edelman, who previously served as a senior biotechnology analyst, brought a deep understanding of the sector to the firm. The firm's inception aimed to bridge the gap between scientific discovery and market realization, fueled by a passion for improving lives through science.Perceptive Advisors has a diverse portfolio of investments, including companies like 4DMT, Achilles Therapeutics, AEGEA Medical, Aquestive, Athenex, Athira Pharma, Black Diamond Therapeutics, CareDx, Chembio, Crinetics Pharmaceuticals, Dova, Earlis, Establishment Labs, Agile Therapeutics, Kiora Pharmaceuticals, Synthego, Orpyx, and Neurosterix. These investments span various areas such as gene therapy, cancer immunotherapies, diabetes management, diagnostics, neurodegenerative diseases, and CRISPR solutions, reflecting the firm's broad engagement across the healthcare value chain.The Perceptive Advisors team comprises a blend of scientific, technical, and investment expertise, including trained technologists, molecular biologists, MDs, and PhDs. This interdisciplinary approach allows the firm to evaluate opportunities from multiple viewpoints, focusing on efficacy and impact. Led by Joseph Edelman as CEO and Portfolio Manager, and Adam Stone as Chief Investment Officer, the team is committed to a collaborative, data-driven approach to identify trends, technologies, and underappreciated assets within the life sciences sector, aiming to accelerate breakthrough innovations and improve patient outcomes.